Biosight is developing innovative therapeutics for hematological malignancies and disorders.
Our lead product, BST-236 (INN aspacytarabine), is an innovative proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity.
As such, BST-236 may serve as an ideal therapy for leukemia, particularly for delivering high doses of cytarabine to medically unfit or older adults who otherwise cannot be treated by effective doses of chemotherapy.
BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following a successful and encouraging Phase 1/2a, which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard therapy.
Additional clinical studies in additional hematological indications are planned to be initiated in 2020.